NeuroSense Therapeutics Ltd.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
/ 
Others were interested in
See all stocksFrequently asked questions
To buy NeuroSense Therapeutics Ltd. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for NeuroSense Therapeutics Ltd. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for NeuroSense Therapeutics Ltd. is NRSN:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
NeuroSense Therapeutics Ltd. has its primary listing on NASDAQ (Small cap). You can trade NeuroSense Therapeutics Ltd. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, NeuroSense Therapeutics Ltd. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include NeuroSense Therapeutics Ltd. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like NeuroSense Therapeutics Ltd..